Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Tianeptine sodium salt
170
CHF
CHF 170.00
In stock
CDX-T0456-M500500 mgCHF 170.00
CDX-T0456-G0011 gCHF 285.00
| Product Details | |
|---|---|
| Synonyms | 7-[(3-Chloro-6,11-dihydro-6-methyldibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid S,S-dioxide sodium salt; S-1574; Stablon |
| Product Type | Chemical |
| Properties | |
| Formula | C21H24ClN2O4S . Na |
| MW | 435.9 . 23.0 |
| CAS | 30123-17-2 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (T) |
| Appearance | White to pale yellow solid. |
| Solubility | Soluble in DMSO (20mg/ml), DMF (30mg/ml), ethanol (10mg/ml) and water (10mg/ml). |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | ZLBSUOGMZDXYKE-UHFFFAOYSA-M |
| Smiles | ClC(C=C1)=CC2=C1C(NCCCCCCC([O-])=O)C(C=CC=C3)=C3N(C)S2(=O)=O.[Na+] |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +20°C |
| Long Term Storage | +20°C |
| Handling Advice |
Keep under inert gas. Very hygroscopic. |
| Use/Stability | Stable for at least 2 years after receipt when stored at RT. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Tianeptine is an atypical antidepressant with diverse actions, most notably on the glutamatergic system. It is a selective facilitator of 5-HT (serotonin) uptake in vitro and in vivo. It attenuates glutamate release and modulates the function of the AMPA receptor. Tianeptine also acts as an agonist of the μ-opioid receptor (EC50s = 194 and 641nM for human and mouse receptors, respectively). Might have anti-inflammatory properties through modulation of TLR and NLRP3 inflammasome signaling pathways.
Product References
(1) T. Mennini, et al.; Naunyn Schmiedebergs Arch. Pharmacol. 336, 478 (1987) | (2) R. Defrance, et al.; Clin. Neuropharmacol. 11, S74 (1988) (Review) | (3) M.G. Simoni, et al.; Brain Res. 574, 93 (1992) | (4) I.T. Uzbay, et al. ; Life Sci. 64, 1313 (1999) | (5) A.J. Wagstaff, et al.; CNS Drugs 15, 231 (2001)| (6) F. Plaisant, et al.; Neuropharmacol. 44, 801 (2003) | (7) B.S. McEwen, et al. ; Mol. Psych. 15, 237 (2010) | (8) V. Szegedi, et al.; Neurochem. Int. 59, 1109 (2011) | (9) S.S. Bilge, et al.; Eur. J. Pharmacol. 681, 44 (2012) | (10) H. Zhang, et al.; Mol. Psych. 18, 471 (2013) | (11) M.M. Gassaway, et al.; Transl. Psych. 4, 1 (2014) | (12) D. Jantas, et al.; Neurotox. Res. 25, 208 (2014) | (13) M.K. Seo, et al.; Psychopharmacol. 233, 2617 (2016) | (14) J. Slusarczyk, et al.; Int. J. Mol. Sci. 19, E1965 (2018)